(-0.03%) 5 467.80 points
(-0.04%) 39 098 points
(0.24%) 17 759 points
(-0.64%) $80.31
(-4.32%) $2.64
(-0.89%) $2 310.10
(-0.10%) $28.84
(2.27%) $1 008.80
(0.28%) $0.936
(0.70%) $10.68
(0.47%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases...
Stats | |
---|---|
Today's Volume | 63 557 |
Average Volume | 1.62M |
Market Cap | 61.34M |
EPS | $-0.470 ( Q1 | 2024-05-09 ) |
Next earnings date | ( $-0.420 ) 2024-08-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.790 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-15 | Hunt Ronald | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Boudreau Helen M | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Liu Hui | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Parmar Kush | Buy | 16 500 | Option (Right to Buy) |
2024-05-15 | Soteropoulos Paula | Buy | 16 500 | Option (Right to Buy) |
INSIDER POWER |
---|
92.07 |
Last 96 transactions |
Buy: 8 046 287 | Sell: 10 802 620 |
Volume Correlation
Rallybio Corporation Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Rallybio Corporation Correlation - Currency/Commodity
Rallybio Corporation Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $-150 000 (0.00 %) |
EPS: | $-1.840 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-167 000 (0.00 %) |
EPS: | $-2.09 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.653 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators